Relapsing polychondritis - A single Centre study in the United Kingdom

A multicenter study of long-term outcomes of relapsing polychondritis in Iran

“…Despite the availability of many biological drugs in Iran, such as TNFis, rituximab and tocilizumab, the lack of approval of these drugs in the treatment of RP by insurance organizations is a possible reason for the underuse of them in studied patients. Of the 5 patients treated with bDMARDs in this report, sustained remission was achieved in 3 patients, which is comparable to the results of Sangle et al 16 report. However, there was no significant difference in the rate of sustained remission in patients treated with bDMARDs versus patients not treated with bDMARDs.…”

“…Disease activity in our study as measured by the RPDAI was 31, which is higher than the only study in which disease activity was measured by this instrument, study Yoshida et al 8 . There was a significant difference in the treatment strategy between the different studies, so that the rate of treatment with biological drugs in the studied patients was lower than the more recent reports 8 , 15 , 16 . Despite the availability of many biological drugs in Iran, such as TNFis, rituximab and tocilizumab, the lack of approval of these drugs in the treatment of RP by insurance organizations is a possible reason for the underuse of them in studied patients.…”

“…Although there was no significant difference in the demographic characteristics and clinical manifestations of the studied patients with previous studies 8 , 10 – 16 , it is difficult to compare treatment results with previous reports due to differences in outcome definitions and lack of data on the remission rate in most studies (Table 6 ). Disease activity in our study as measured by the RPDAI was 31, which is higher than the only study in which disease activity was measured by this instrument, study Yoshida et al 8 .…”

“…They reported increase in the prescription of csDMARDs and bDMARDs in 2019 compared to 2009 and a decrease in RP mortality from 22 to 3% during this time period 15 . Sangle et al 16 in a retrospective study reported a diagnosis delay of 55 weeks. Combination therapy with prednisolone and DMARDs was performed in 97% of patients and 63% eventually required biological drugs 16 .…”

“…Sangle et al 16 in a retrospective study reported a diagnosis delay of 55 weeks. Combination therapy with prednisolone and DMARDs was performed in 97% of patients and 63% eventually required biological drugs 16 . However, mortality was 18% 16 .…”